PMID- 30648575
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20220809
IS  - 2224-6614 (Electronic)
IS  - 1021-9498 (Print)
VI  - 27
IP  - 1
DP  - 2019 Jan
TI  - Antidepressant and anxiolytic effects of the proprietary Chinese medicine 
      Shexiang Baoxin pill in mice with chronic unpredictable mild stress.
PG  - 221-230
LID - 10.1016/j.jfda.2018.08.001 [doi]
AB  - Depression and anxiety often co-occur with cardiac diseases. The Shexiang Baoxin 
      pill (SBP) is a proprietary Chinese medicine initially used to treat cardiac 
      conditions. This study explored whether SBP has antidepressant and anxiolytic 
      effects in addition to hormonal and psychotropic mechanisms. Mice underwent 6 
      weeks of chronic unpredictable mild stress (CUMS) to induce depression- and 
      anxiety-like behavior. During the 6-week experiment, mice received SBP at 
      intragastric doses of 20.25 mg/kg or 40.5 mg/kg daily. Animals were then tested 
      for depression in sucrose preference, forced-swimming, and tail suspension 
      paradigms, and for anxiety in open field and elevated plus maze tests. Both SBP 
      doses significantly reduced anhedonic behavior in the sucrose preference test; 
      the high SBP dose also increased the number of entries into the central zone of 
      the open field. SBP-treated mice had markedly lower blood levels of 
      corticotrophin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) 
      than stressed mice treated with vehicle. Either low- or high-dose SBP reversed 
      stress-induced reductions of norepinephrine (NE) and dopamine (DA) metabolites 
      and the expression levels of brain-derived neurotrophic factor (BDNF), nerve 
      growth factor (NGF), and glial cell-derived neurotrophic factor (GDNF) in related 
      brain regions. These results suggest that SBP could prevent and alleviate 
      prolonged stress-induced anhedonia and anxiety in association with its 
      suppression of the hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, 
      modulation of brain monoamine neurotransmitter metabolism and neurotrophins. SBP 
      may be particularly suitable for the management of depressive and anxiety 
      disorders in patients with cardiac conditions.
CI  - Copyright (c) 2018. Published by Elsevier Taiwan LLC.
FAU - Zhou, Xi-Dan
AU  - Zhou XD
AD  - School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 
      Hong Kong, China.
FAU - Shi, Dong-Dong
AU  - Shi DD
AD  - School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 
      Hong Kong, China.
FAU - Zhang, Zhang-Jin
AU  - Zhang ZJ
AD  - School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 
      Hong Kong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180824
PL  - China (Republic : 1949- )
TA  - J Food Drug Anal
JT  - Journal of food and drug analysis
JID - 101630927
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (shexiang baoxin)
SB  - IM
MH  - Animals
MH  - Anti-Anxiety Agents/*administration & dosage
MH  - Antidepressive Agents/*administration & dosage
MH  - Brain-Derived Neurotrophic Factor
MH  - Depression/*drug therapy/psychology
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Humans
MH  - Hypothalamo-Hypophyseal System/drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pituitary-Adrenal System/drug effects/metabolism
PMC - PMC9298624
OTO - NOTNLM
OT  - Anxiety
OT  - BDNF
OT  - Depression
OT  - HPA axis
OT  - Shexiang Baoxin pill (SBP)
COIS- Conflicts of interest The authors declare that they have no competing interests.
EDAT- 2019/01/17 06:00
MHDA- 2020/03/24 06:00
PMCR- 2018/08/24
CRDT- 2019/01/17 06:00
PHST- 2018/01/21 00:00 [received]
PHST- 2018/07/15 00:00 [revised]
PHST- 2018/08/03 00:00 [accepted]
PHST- 2019/01/17 06:00 [entrez]
PHST- 2019/01/17 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
PHST- 2018/08/24 00:00 [pmc-release]
AID - j.jfda.2018.08.001 [pii]
AID - jfda-27-01-221 [pii]
AID - 10.1016/j.jfda.2018.08.001 [doi]
PST - ppublish
SO  - J Food Drug Anal. 2019 Jan;27(1):221-230. doi: 10.1016/j.jfda.2018.08.001. Epub 
      2018 Aug 24.